quetiapine fumarate + SSRI/Clomipramine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Obsessive Compulsive Disorder
Conditions
Obsessive Compulsive Disorder
Trial Timeline
Apr 1, 2002 → Mar 1, 2006
NCT ID
NCT00254735About quetiapine fumarate + SSRI/Clomipramine
quetiapine fumarate + SSRI/Clomipramine is a phase 3 stage product being developed by AstraZeneca for Obsessive Compulsive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00254735. Target conditions include Obsessive Compulsive Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00254735 | Phase 3 | Completed |
Competing Products
17 competing products in Obsessive Compulsive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine | Eli Lilly | Approved | 85 |
| Fluvoxamine maleate + Placebo | AbbVie | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 2 | 52 |
| Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo) | Novartis | Approved | 85 |
| Bitopertin + Placebo + SSRI | Roche | Phase 2 | 52 |
| sertraline | Pfizer | Pre-clinical | 22 |
| pregabalin + Placebo | Pfizer | Approved | 84 |
| Sertraline + Levetiracetam + Placebo | UCB | Phase 2/3 | 62 |
| Escitalopram | Lundbeck | Approved | 82 |
| Escitalopram + Placebo oral tablet | Lundbeck | Approved | 82 |
| Valbenazine + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| RG1068 (Synthetic Human Secretin) | Repligen | Phase 2 | 49 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 2/3 | 60 |
| Troriluzole (BHV-4157) | Biohaven | Phase 3 | 72 |
| Nitrous Oxide + Nitrogen | Brain Biotech | Phase 2 | 44 |